Navigation Links
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Date:6/30/2008

- Product appears safe with no dose-limiting toxicities -

- Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance

into pivotal clinical program in 2009 -

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme, and established the dose for subsequent clinical trials, therefore achieving the pre-defined primary objective of the study. In addition, there were no neutralizing antibodies to rHuPH20 detected and the plasma concentration of mitomycin was either non-measureable or negligible and well below the threshold that may be predictive for myelosuppression (a decrease in bone marrow activity, resulting in fewer red blood cells, white blood cells, and platelets).

The study also provided support for future pivotal trial development that will incorporate the highest combination dose studied in the current trial, mitomycin plus 800,000 Units of rHuPH20. Commenting on the results, Richard C. Yocum, M.D., Vice President of Clinical Development and Medical Affairs at Halozyme stated, "We are pleased the study demonstrated that Chemophase was well-tolerated and produced no dose-limi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  Cyberonics, Inc. (NASDAQ: CYBX ... treatment and management of epilepsy, today announced it will ... March 11, 2015, in Miami . ... Chief Executive Officer, will speak at 1:05 PM Eastern ... chat format, and no formal materials will be presented.  ...
(Date:3/3/2015)... March 3, 2015  The eleventh annual Tucson Symposium ... the world,s top research scientists, academics, oncologists and pathologists ... and learn about new outcomes in patient treatments that ... Each year Ventana Medical Systems, Inc. (Ventana), ... the Tucson Symposium at the Hilton El Conquistador in ...
(Date:3/3/2015)... 3, 2015 /CNW/ - ChipCare Corporation, a University of ... for HIV and other infectious and non-communicable diseases ... to bring its first-generation product to market while ... (Photo: http://photos.prnewswire.com/prnh/20150303/179107 ) ... simple, accurate and affordable diagnostic tests makes it ...
Breaking Medicine Technology:Global scientific collaborators to explore latest pathology and oncology advancements at Tucson Symposium 2ChipCare Closes Oversubscribed $5 Million Series A Financing 2ChipCare Closes Oversubscribed $5 Million Series A Financing 3
... 23, 2011 Valeant Pharmaceuticals International, Inc. (the "Company" ... Notice of Intention to make a normal course issuer ... that the TSX has accepted the Notice of Intention. ... to purchase for cancellation, commencing August 25, 2011, 1,000,000 ...
... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical applications, ... Annual Global Investment Conference. The conference will be held at ... 11-13, 2011. Bacterin,s chairman and CEO, Guy Cook, ...
Cached Medicine Technology:Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 2Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid 3Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011 2
(Date:3/3/2015)... Introducing 3D Digital Technologies to ... recognized leader in Digital Dentistry. Acute precision in ... dental replicas, leaving no room for error during ... professionals are able to significantly reduce “chair time” ... remarkable quality while reducing labor and material costs ...
(Date:3/3/2015)... BOCA RATON, Fla - (March 3, 2015) (PRWEB) March ... First Class Vacations, Inc. (FCV), an innovator in the ... next step in his trailblazing expansion plan. To fulfill ... forward with the addition of 400 fun, exciting and ... Raton, Florida headquarters and a news sales center planned ...
(Date:3/3/2015)... March 03, 2015 According to ... http://www.idataresearch.com ), market saturation has made neurosurgery navigation ... the United States. Unit sales growth moderately increased ... as facilities replace older systems, and as new ... market is very much a replacement and upgrade ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 eMedEvents, ... and continuing medical education (CME) credit information, has ... for doctors was initially launched in the United ... of its kind in the field of healthcare ... launch of this Denver, Colorado-based start-up company was ...
(Date:3/3/2015)... 2015 State after state prove ... of probation programs aimed to rehabilitate nonviolent drug ... (tax) cost of incarcerating violators of drug laws, ... alcohol addiction treatment. Governor Bruce Rauner ( R)has ... Illinois' drug and alcohol statewide Department of Alcoholism ...
Breaking Medicine News(10 mins):Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 2Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 3Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 2Health News:First Class Vacations, Inc. Expansion Plan Creates 400 Jobs In South Florida 3Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 2Health News:Neurosurgery Navigation System Market Reaches Saturation in the United States 3Health News:eMedEvents Launches Online Medical Conference, Speaker and CME Platform in India 2Health News:Gov. of Illinois, Bruce Rauner, Suggests Cutting 25 Million for Drug Rehabilitation, Harbor Village Comments 2
... 18 ReBuilder,Medical Technologies, Inc. (Pink Sheets: ... world-renowned medical device inventor David B.,Phillips, Ph.D., ... organization and facilitation. (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ... many companies are outsourcing customer service to,overseas ...
... Prostatitis is a common,problem, yet the antibiotics physicians ... associated with this condition work in only a ... condition have a form called,chronic nonbacterial prostatitis, which ... edition of Harvard Medical School,s Perspectives on Prostate,Disease ...
... is the World,s First Accurate Non-Contact Clinical Thermometer, ... Inc., a division of,American Scientific Resources, (ASFX-OTC) today ... the first non-contact clinical,thermometer in the world, now ... Thermofocus 5-in-1, made in Italy and long,recommended by ...
... University of Jerusalem have developed a novel approach for ... of providing improved movements of natural or artificial limbs ... , Neuroscientists have long been working towards achieving a ... behavior, and especially between neural activity in the motor ...
... A new study from the USC Davis School of ... negative mental or physical health effects as a result ... , The findings, which appeared in the September ... and physical health differences between African-American and white caregivers. ...
... Under Bed Nets, NEW YORK, Oct. 18 ... contribute to the distribution of 1.4,million bed nets to ... the Malagasy government, the campaign will ensure that virtually,every ... a bed net. Sumitomo,Chemical donated 110,000 long-lasting insecticide-treated Olyset ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:Antibiotics May Not Help Men's Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 3Health News:Brain measurements could lead to better devices to move injured or artificial limbs 2Health News:Brain measurements could lead to better devices to move injured or artificial limbs 3Health News:USC study examines effects of caregiving 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 2Health News:Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: